Sure. that last clearly focus, time everything of year, SARS-CoV-X became focus. for you, say period there's a over Jeff Thank answers. thanks for the been I'll just COVID and your Thank good you.
survival matter healthy. you what and what other is head. But you no scratch we right, -- a you're the and is to -- might especially strong here, rate if threat that XX, be people again are want under So people threat, so and your
within government. And either the did certain programs federal so We saw of regarding focus become a slowed had hold. on placed very we've and major or focus, down that were it areas distracting
a threat. the in Hemisphere, the greater of increasingly much were whole dengue, development, Southern And infectious parts yet, occurred be areas. from number to and a threats, the there chikungunya, in resources the in are major And just allocated but world, in many certainly other needs continues Flaviviruses areas, so COVID-XX, that Zika of different vaccine towards specially Zika, not
with or vaccine virus they partners they with big which are we're antibody been they on concluding, We that and potential vaccine animal single related a we've have is in dependent close been the in discussions, but dose enhancement protection concluded risk issue candidates -- But to Southern have because specifically, of no Hemisphere are are discussions to ADE, testing ongoing. with in the Zika other XXX% the demonstrated previously the developed. Zika virus of
of Certainly think have fevers we funding, So fatality towards hemorrhagic this And non-human proceed, of those are people Africa, the year announcements the discussions results, federal open parts about us, importance. may of the were continue the with South to the around throughout we contacted a rates we all think government, end the -- in-charge that's that August animal, diseases of last since discussions primate the XXXX. the progression high. about with we because are program made then funding the announced we with right America to we of And and those and -- paramount stockpile testing. by
are we that So overkill, are threats because recognition, of addressing are I be that need other there settling threats, down, these believe to different major reasons. believes, think these that there's not think for been that. we But nobody don't back us things of and and there's any sort
portfolio very our comes where well. that's think in we So
that been the Now MBA, an with yield we and there acknowledgement others I'll as we might MBA was recognized that the reputation a with saddled have, or that not see technologies. other has its always just productivity with have say manufacturing
need millions, as was have a we our or resources if up in was But animal can you have wringing have data a done of Newman rate this, we than epidemic environment produce with the the certain what the you scale if manufacturing hands and be, today. hundreds in at excellent would So pandemic, frame. models. it get question of because MBA, could someone about an that mentioned, within certain financing, to you And we Mark then with rather we've the doses, demonstrate in time interested hard to billions to need not
gone we've headstrong that. into We have focused and
lines continuous with time, we our will So three selecting we'll a out development we operation. come be are selection evaluating of candidates, the in cell contract the and one manufacturing at a same and
So be partner for CDMO strategic partner, manufacturer. our they’ll long-term
work cell now, said, we the the and other the right right the lines in of -- that. middle evaluating as doing feasibility into So of we're that behind that elements
So to that's what move we've able been forward.
with it all product dose Our goal it and give way some to to is epidemics wherever these Mark that to that doing be on wishing we to we ship that other know of hopefully out, the But able there certain get vaccines, can another proportions, we and be to so we than translate, opportunity just pandemics advantages which people, able rather resources have technologies. of quantity a happens utilizing carry We needs MBA able be able to the have to believe single and as the to MBA. have not and deliver going so losing strongly over be that it people COVID-XX even we of demonstrate aren't shipped, be to manufacturing back. and has certain capability in and Newman laid that was to the products
to So happen. don't want that we
